Quick Answer
Ernexa Therapeutics Inc. reported Net Income of -$14.08 million for fiscal year 2025.
Ernexa Therapeutics Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$14.08M | +68.4% |
| 2024 | -$44.54M | -105.6% |
| 2023 | -$21.67M | +11.8% |
| 2022 | -$24.58M | +79.9% |
| 2021 | -$122.55M | -361.9% |
| 2020 | -$26.53M | -1196.1% |
| 2019 | -$2.05M | -690.3% |
| 2018 | -$259.0K | +76.0% |
| 2017 | -$1.08M | +63.2% |
| 2016 | -$2.92M | +59.5% |
| 2015 | -$7.23M | -43.7% |
| 2014 | -$5.03M | -377.7% |
| 2013 | -$1.05M | -5.8% |
| 2012 | -$995.0K | +70.9% |
| 2011 | -$3.42M | -754.8% |
| 2010 | -$400.0K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.24M | +95.3% | +60.5% |
| June 30, 2025 | -$3.14M | +43.2% | +61.7% |
| March 31, 2025 | -$8.20M | -23.4% | +69.2% |
| September 30, 2024 | -$26.60M | -375.8% | -381.2% |
| June 30, 2024 | -$5.53M | -22.6% | +16.8% |
| March 31, 2024 | -$6.65M | -22.7% | -18.9% |
| September 30, 2023 | -$5.59M | +23.6% | -24.0% |
| June 30, 2023 | -$4.51M | -32.7% | +16.8% |
- Ernexa Therapeutics Inc. showed an increase of +68.4% in Net Income compared to the prior fiscal year.
- Over the 2010–2025 period, Ernexa Therapeutics Inc.’s net income has declined by 3421.0% (from -$400.0 thousand to -$14.08 million).
- The most recent figure is from Ernexa Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: